UTI Healthcare Fund · Direct · Growth
NAV
₹398.0957
as of 17 Nov 2026
Expense Ratio
1.31%
Lumpsum returns (CAGR)
- 1Y
- +21.20%
- 3Y
- +23.07%
- 5Y
- +17.72%
- Since Inception
- +16.52%
SIP returns (XIRR)
- 1Y
- +30.00%
- 3Y
- +19.36%
- 5Y
- +21.93%
- Since Inception
- +13.87%
Performance Comparison
Sectoral allocation
as of 31 Oct 2026- Pharmaceuticals & Biotechnology68.69%
- Healthcare Services25.75%
- Healthcare Equipment & Supplies1.14%
- Chemicals & Petrochemicals0.97%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with UTI Healthcare Fund - Regular Plan - Growth Option
- 1Sun Pharmaceuticals Industries7.44%
- 2Divis Laboratories Ltd.6.46%
- 3Dr Reddys Laboratories Ltd.5.78%
- 4Ajanta Pharma Ltd.4.29%
- 5Max Healthcare Institute Ltd4.20%
- 6Gland Pharma Ltd.3.89%
- 7Apollo Hospitals Enterprise Lt3.83%
- 8Alkem Laboratories Ltd3.66%
- 9Lupin Ltd.3.65%
- 10Global Health Ltd.3.37%
What this fund does
UTI Healthcare Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 13 years. It benchmarks its performance against BSE Healthcare TRI. The current expense ratio is 1.31%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations